MARK S. KIPNES, MD PUBLICATIONS

ABSTRACTS/POSTER PRESENTATIONS

Virtual Endocrinologist: Hospital Diabetes Management Via Telemedicine. Mark S. Kipnes, 1 Steve Haffner, 2 Teri Lightner, 3 Rajesh Garg, 4 Firas Akhrass, 5 Vijayveer S. Pamar, 6 Amna a. Salhin, 7 Jacob Vadakekalam, 8 Javier Pena, 9 Syndy Kirkland, 10 Merri Pendergrass, 11. 1 DGD Clinic, San Antonio, TX; 2 San Antonio, TX; 3 See My Doc, Harlington, TX; 4 Harvard Medical School, Boston, MA; 5 DGD Clinic, San Antonio, TX; 6 DGD Clinic, San Antonio, TX; 7 DGD Clinic, San Antonio, TX, 8 DGD Clinic, San Antonio, TX.; 9 VENP, Harlingen, TX; 10 VENP, Harlingen, TX; 11 University of Arizona, Tucson, AZ. Abstract presented at the ADA 76th Scientific Sessions New Orleans, LA June 10-14, 2016.

Metabolic Effects and Safety of Single Rising-dose Sitagliptin in Adolescents with Type 2 Diabetes. Larry A. Fox,1 Iain Fraser,2 Naomi Neufeld,3 Mark S. Kipnes,4 Tracie L. Miller,5 Phillip S. Zeitler,6 Henry Rodriguez,7* JocelynGilmartin,2 Susan J. Lee,2 Jaclyn K. Patterson,2 Xiujiang Li,2 Lata Maganti,2 Wen-Lin Luo,2** Daniel Tatosian,2 Edward A. O’Neill,2 and S. Aubrey Stoch2. © Merck, Sharp & Dohme Corp. 2013. Presented at the American Diabetes Association 73rd Scientific Sessions, June 21-25, 2013, Chicago, IL. 1Nemours Children’s Clinic, Jacksonville, FL; 2Merck, Whitehouse Station, NJ; 3Neufeld Medical Group, West Hollywood, CA; 4DGD Clinic, San Antonio, TX; 5University of Miami, Miami, FL; 6Children’s Hospital Colorado, Aurora, CO; 7James Whitcomb Riley Hospital for Children, Indianapolis, IN; *Present affiliation: University of South Florida, Tampa, FL; **Present affiliation: Bristol-Myers Squibb, Princeton, NJ

Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of VRS-859 in Patients with Type 2 Diabetes. JEFFREY L. CLELAND, RONNIE ARONSON, Eric HUMPHRISS, CAMILLE SHORE, RONG ZHOU, Mark S. KIPNES. Redwood City, CA; Toronto, Canada; Cincinnati, OH; San Antonio, TX. Presented at the American Diabetes Association 72nd Scientific Sessions, Philadelphia, PA, June 8-12, 2012.

Safety, Tolerability and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension. Mark S. Kipnes, MD. Published online in The Journal of Clinical Hypertension – JCH12474, January 24, 2015.


A 16-Week Open-Label, Multicenter, Pilot Study Assessing Insulin Pump Therapy in Patient with Type 2 Diabetes Suboptimally Controlled with Multiple Daily Injections. Juan P. Frias, MD1, Bruce W. Bode, MD2, Timothy S. Bailey, MD3, Mark S. Kipnes, MD4, Rocco Brunelle, MS5, Steven V. Edelman, MD1. Article – July 2011 – Journal of Diabetes Science and Technology.


Sodium-Glucose Cotransporter 2 Inhibitors In The Treatment of Type 2 Diabetes: A review of Phase II and Phase III trials. Mark Kipnes1 Article Clinical Investigations - 2011. 145-156

P3 Macimorelin, An Oral Ghrelin-Mimetic GH Secretagogue, as a Potential Diagnostic Test for Adult GH Deficiency. B.M.K. Biller; K.C.J. Yuen; V. Bonert; M. Chen; A. Dobs; J.M. Garcia; M. Kipnes; M. Molitch; R. Swerdluff; C. Want; D. Cook; I.R. Altemose; G. R/ Merriam. Article – Growth Hormone & IgF Research Dec 2010


Insulin Pump Therapy in Patients with Type 2 Diabetes Safely Improve Glycemic Control Using a Simple Insulin Dosing Regimen. Steven V. Edelman MD1, Bruce W. Bode, MD2, Timothy S. Bailey, MD,3 Mark S. Kipnes, MD4, Rocco Brunette, M.S5,., Xiaojing Chen, M.S.6, and Juan P. Frias, MD6. Article Diabetes Technology & Therapeutics, Volume 12, Number 8, 2010. © Mary Ann Liebert, Inc. Publishers DOI: 10.1089/dia.2010.0034.


Safety and Effectiveness of Realize Adjustable Gastric Bandz: 3-Year Prospective Study in The United States. E H Phillips; Jaime Ponce; Scott A. Cunneen; Mark S. Kipnes; […] Natan Zundel. Original Article Surgery for Obesity and Related Diseases. Sept 2009


“Efficacy and safety of the dipeptidyl-peptidase 4 inhibitor alogliptin in patients with Type 2 diabetes inadequately controlled by Glyburide monotherapy.” R.E. Patley1, M.S. Kipnes2, P.R. Fleck3, C. Wilson3, and Q. Mekki3, on behalf of the Alogliptin Study 007 Group. Online publication journal Diabetes, Obesity and Metabolism, February 2009 issue.

Efficacy and Safety of Alogliptin and Glyburide Combination Therapy in Patients with Type 2 Diabetes. Penny Fleck; Q. Mekki; Mark Kipnes; […] Richard E. Pratley. Original Article Diabetologia Sep 2008

Interim Results of a Phase I/II Clinical Trial of a DNA Plasmid (BHT-3021) for Type 1 Diabetes. Peter A. Gottlieb, George S. Eisenbarth, Mark Kipnes, Robert Ratner, Jennifer Rockwell, Rebecca Wagner, Hideki Garren, Aurora, CO, San Antonio, TX, Hyattsville, MD, Palo Alto, CA. Conference Paper Printed in the Scientific Sessions Abstract Book, the June 2008 supplement to the journal, Diabetes. (American Diabetes Association 68th Scientific Sessions, June 6-10, 2008 in San Francisco, CA.)

M1254 Safety and Functionality of Gastric Electrical Stimulation with TANTALUS® On Glycemic Control in Overweight Subjects with Type 2 Diabetes – Results of a Clinical Feasibility Study on An Investigational Device. Claudia Sanmiguel; Jeffrey L. Conklin; Mark Kipnes; […] Edy Soffer. Original Article in Gastroenterology Apr 2008.


Sitagliptin. Original Article by Mark Kipnes. Drugs Sep 2007


Effect of The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients with Type 2 Diabetes. Pablo Aschner; Mark Kipnes; Jared K. Lunceford; D. Williams-Herman [...]. Article published in Diabetes Care Jan 2007

Tolerability and Pharmacokinetics of Metformin and the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Co-Administered in Patients with Type 2 Diabetes. Gary A. Herman; Arthur J. Bergman; Bingming Yi; Mark Kipnes. Article in Current Medical Research and Opinion. Nov 2006.

Sitagliptin Monotherapy Improved Glycemic Control in Patients with Type 2 Diabetes. Pablo Aschner, Mark Kipnes; Jared K. Lunceford […] D. Williams-Herman. Conference Paper read at the 42nd Annual Meeting of the American Diabetes Assn Sep 2006

Sitagliptin Monotherapy Improved Glycemic Control in Patients with Type 2 Diabetes. Pablo Aschner; Mark Kipnes; Jared K. Lunceford; D. Williams-Herman. Conference Paper read at the 42nd Annual Meeting of the American Diabetes Association Sep 2006


Sitagliptin Monotherapy Improved Glycemic Control in the Fasting and Postprandial States and Beta-Cell Function after 24 Weeks in Patients with Type 2 Diabetes (T2DM). PABLO ASCHNER, MARK KIPNES, JARED LUNCEFORD, CAROLYN MICKEL, MICHAEL DAVIES, DEBORA WILLIAMS-HERMAN. Bogota, Columbia, San Antonio, TX, Rahway, NJ. Article in Diabetes Jan 2006


Differences in Glucose Tolerance Between Fixed-dose Antihypertensive Drug Combinations in People with Metabolic Syndrome. Mark S. Kipnes, MD. Published in Diabetes Care 2006; 29 (12): 2592-2597

The Impact of Insulin Glargine on Clinical and Humanistic Outcomes in Patients Uncontrolled On Other Insulin and Oral Agents: An Office-Based Naturalistic Study. Jerome S. Fischer; Trent McLaughlin; Litza Loza; Mark S. Kipnes; […]. Article Current Medical Research and Opinion Nov. 2004


"Effects of Simvastatin on the Lipid Profile and Attainment of Low Density Lipoprotein Cholesterol Goals When Added to Thiazolidinedione Therapy in Patients with Type 2 Diabetes Mellitus: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial." Andrew J. Lewin, MD, Mark S. Kipnes, MD, Luigi F. Meneghini, MD, Diane J. Plotkin, PhD, Inna T. Perevozskaya, PhD, Sukrut Shah, PhD, Darbie L.
Maccubbin, PhD4, Yale B. Mitchel, MD4 and Jonathan A. Tolbert, MD4 for the Simvastatin/Thiazolidinedione Study Group*  Article in Clinical Therapeutics /Vol.26, No. 3, Mar2004.

“Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Patients with Type 2 Diabetes.”  Mark S. Kipnes, MD3; Paresh Dandona, MD3; Devjit Tripathy; MD3; J. Gordon Still, PhD3.; Gordana Kosutic, MD3  Diabetes Care Volume 26, Number 2, February 2003, pp:421-426. 2003.


“Sugar-Free Zinc Gluconate Glycine Lozenges (Cold Eeze®) Do Not Adversely Affect Glucose Control in Patients with Type 1 or Type 2 Diabetes Mellitus”. Sherwyn L. Schwartz, M.D.; Jerome S. Fischer, M.D.; Mark S. Kipnes, M.D. Article published in American Journal of Therapeutics, 1075-2765 © July 2001 Lippincott Williams & Wilkins pp. 006-0611


Domperidone Improves Health-Related Quality of Life (HRQOL) in Patients with Gastrointestinal Symptoms Associated with Diabetic Gastroparesis. Eamonn M. Quigley; N.K. Leidy; M. Murray; M. Kipnes; [...] Article published in Gastroenterology, Apr 1997.

“Management of Gestational Diabetes in the Obese Patient”. Terri Ryan, RN, CDE; Jasso-Glavy, Carla, MS, RD, CDE; Kipnes, Mark S., M.D. and their health care team. Diabetes Spectrum, July/August 1995, Volume 8, Number 4, pp. 190 -191

“Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients”. Jabri, Nabeel, MD.; Schalch, Don S., MD; Schwartz, Sherwyn L., MD; Fischer, Jerome S., MD; Kipnes, Mark S., MD; Radnik, Barbara J., RN; Turman, Nancy J., MD; Marcsin , Victoria S., MD and Guler, Hans-Peter, MD. Article published in Diabetes, A Journal of the American Diabetes Association, March 1994, Volume 43

“Effects of Short -Term Insulin Therapy upon Therapeutic Response to Glipizide”. Schwartz, Sherwyn, MD; Fischer, Jerome S., MD; Kipnes, Mark S., MD and Boyle, Mary, RN., The American Journal of Medicine, September 18, 1987, Volume 83, Supplement 3A, pp. 22 – 30

“Guidelines to Diabetes Management for the Primary Care Physician", Editorial Board, Professional Education Committee, American Diabetes Association Texas Affiliate, 1985

A Study to Assess the Metabolic Effect of Ranolazine When Added to Ongoing Non-Insulin Medical Therapy in Subjects with Type 2 Diabetes Mellitus (T2DM). Mark S. Kipnes, MD, mkipnes@dgdclinic.com, Cetero Research, San Antonio, TX, United States. Harold E. Bays, MD, HBaysMD@aol.com, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, United States. Peter Staehr, MD, Peter.Staehr@gilead.com, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States. Rajneesh Nath, MD, PhD, Rajneesh.Nath@gilead.com, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States. David S. Kwon, MD, PhD, David.Kwon@gilead.com, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States. Millie D. Gottwald, Pharm D., Millie.Gottwald@gilead.com, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States. Luiz Belardinelli, MD, Luiz.Belardinelli@gilead.com, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States.  2011

Topical Clonidine for Treatment of Painful Diabetic Neuropathy: a Randomized Double Blind Phase IIb Clinical trial. James N. Campbell, Prof., MD, jcampbell@arciontherapeutics.com, Arcion Therapeutics, Baltimore, MD, United States. Mark S. Kipnes, Dr., MD, mkipnes@dgdclinic.com, Cetero Research/Diabetes and Glandular Disease Clinic, San Antonio, TX, United States. Michael C. Rowbotham, Prof., MD, RowbotM@cpmcl.org, California Pacific Medical Center Research Institute, Scientific Director, San Francisco, CA, United States. Karin L. Petersen, Prof., MD, Karin.petersen@ucsf.edu, University of California, Neurology, San Francisco, CA, United States. Bruce C. Stouch, Dr. PhD, bstouch@arciontherapeutics.com, Arcion Therapeutics, Baltimore, MA, United States. Margaret Kelly, Ms., MS, mkelly@arciontherapeutics.com, Arcion Therapeutics, Baltimore, MD, United States. Claudia M. Campbell, Dr., PhD, ccampb41@jhu.edu, Johns Hopkins University School of Medicine, Psychiatry, Baltimore, MD, United States. Kerrie Brady, Ms., MS, MBA, kbrady@arciontherapeutics.com, Arcion Therapeutics, Baltimore, MD, United States. William K. Schmidt, Dr., PhD,
Continuous Subcutaneous Insulin Infusion (CSII) in Type 2 Diabetes: Reductions in A1c, Mean Glucose, and Variability. Author Block: H. Anhalt1, D. Rodbard2, T. Bailey3, B. Bode4, R. Brunelle5, S. Edelman6, J.P. Frias1, M.S. Kipnes7; Animas Corporation, West Chester PA, USA, 3AMCR Institute Inc., Escondido CA, USA. 4Atlanta Diabetes Associates, Atlanta GA, USA. 5B2S Consulting, Carmel, IN, USA. UCSD/VA TCOYD, San Diego, CA, USA. 7Cetero Research/Diabetes and Glandular Disease Clinic, San Antonio, TX, USA. Presented at the ADA 71st Scientific Sessions, San Diego, CA, June 24-28, 2011


A Study to Assess the Metabolic Effects of Ranolazine When Added to Ongoing Non-Insulin Medical Therapy in Subjects with Type 2 Diabetes Mellitus (T2DM). 1. Mark S. Kipnes, MD, mkipnes@dgdclinic.com, 2106148612, Cetero Research, San Antonio, TX, United States 2. Harold E. Bays, MD, HBaysMD@aol.com, 5025155672, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, United States 3. Peter Staehr, MD, Peter.Staehr@gilead.com, 6505243883, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States 4. Rajneesh Nath, MD, PhD, jrneesh.Nath@gilead.com, 6505243877, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States 5. David S. Kwon, MD, PhD, David.Kwon@gilead.com, 6505221571, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States 6. Millie D. Gottwald, Pharm D., Millie.Gottwald@gilead.com, 6505225903, Gilead Sciences, Clinical Pharmacology, Foster City, CA, United States 7. Luiz Belardinelli, MD, Luiz.Belardinelli@gilead.com, 6505243889, Gilead Sciences, Cardiovascular Therapeutic Area, Foster City, CA, United States. Presented at the ADA 71st Scientific Sessions, San Diego, CA, June 24-28, 2011.


A 16-Week Open-Label, Multicenter, Pilot Study Assessing Insulin Pump Therapy in Patients with Type 2 Diabetes Suboptimally Controlled with Multiple Daily Injections. Juan P. Frias, MD1, Bruce W. Bode, MD2, Timothy S. Bailey, MD,3 Mark S. Kipnes, MD4, Rocco Brunelle, MS5, Steven V. Edelman, MD1. Presented at the European Association for the Study of Diabetes (Stockholm, Sweden, September 2010. “Macimorelin, an Oral Ghrelin-Incretin mimetic GH Secretagogue, as a Potential Diagnostic Test for Adult GH Deficiency” has been accepted for poster presentation at the 5th International Congress of the GRS-IGF Society at the Sheraton New York towers in New York, NY USA, October 3-7, 2010.


Insulin Pump Therapy in Patients with Type 2 Diabetes Safely Improve Glycemic Control Using a Simple Insulin Dosing Regimen. Steven V. Edelman MD1, Bruce W. Bode, MD2, Timothy S. Bailey, MD,3 Mark S. Kipnes, MD4, Rocco Brunelle, M.S.5, Xiaoqing Chen, M.S.6, and Juan P. Frias, MD6. Diabetes Technology & Therapeutics, Volume 12, Number 8, 2010. © Mary Ann Liebert, Inc. DOI: 10.1089/dia.2010.0034.

A One-Year Study to Assess the Efficacy, Safety and Tolerability of Taranabant, a Highly Selective CB1R Inverse Agonist, in Overweight and Obese Patients with Type 2 Diabetes: 36-Week Results. Troels Wolthers¹, Mark Kipnes², Priscilla Hollander³, Ira Gantz⁴, Thomas Seck⁵, Ngozi Erondu⁵, Yue Shentu⁵, Kaifent Lu⁵, Shailaja Suryawanshi⁶, Margaret Chou⁷, Michael J. Davies⁴, Steve Heymsfield⁴, Keith D. Kaufman⁴, John M. Amatruda⁴. ¹Merck Sharp & Dohme, New South Wales, Australia. ²Diabetes and Glandular Disease Research Associates, San Antonio, Texas, USA, ³Endocrinology Center, Baylor University Medical Center, Dallas, TX, USA, ⁴Merck Research Laboratories, Rahway, NJ USA. ⁵th AOCO Presentation 2009, Mumbai, India

The efficacy and safety of 12-week treatment with fenofibric acid co-administered with low-- or moderate-dose statin in patients 65 years or older with mixed dyslipidemia. Peter H. Jones¹, Mark S. Kipnes², Maria L. Rios³, Carolyn M. Setze⁴, Maureen T. Kelly⁴, Darryl J. Sleep⁴. ¹Baylor College of Medicine, Houston, TX. ²DGD Research Associates, San Antonio, TX. ³, ⁴Abbott, Abbott, Park, IL. Published in J Clin Lipidol, 2009.

“Continuous Subcutaneous Insulin Infusion in Patients with Type 2 Diabetes Safely Improved Glycemia Control Using a Simple Insulin Dosing Regimen.” Selected for Poster Presentation at the 45th EASD Annual Meeting, Vienna, September 29 – October 2, 2009.

Gastric Electrical Stimulation with the TANTALUS® System in Obese Type 2 Diabetes Patients: Effect on Weight and Glycemic Control. Sanmiguel CHEST PAIN; Conklin JL; Cunneen SA; Barnett P; Phillips EH; Kipnes M; Pilcher J; Soffer EE. Abstract Journal Diabetes Sci Technol July 2009

Efficacy and Safety of The Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients with Type 2 Diabetes InadequatelyControlled by Glyburide Monotherapy. Fraley RE¹, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin 007 Group. Abstract in Diabetes Obesity & Metabolism Feb 2009

Performance of the TRUE2go (TM) Blood Glucose System: A Novel Integrated System for Meter and Strips; Douglas E. Bell, Ph.D; Hal Joseph, RPA-C, CDE; Mark S. Kipnes, MD; Jason Manko, BS; Harry Morris, DO, MPH, Home Diagnostics, Inc., Fort Lauderdale, Florida, USA 2009


Sitagliptin, A Selective DPP-4 Inhibitor, Improves Glycemic Control when Added to a Sulfonylurea or to a Sulfonylurea and Metformin in Patients with Type 2 Diabetes. Kjeld Hermansen, Mark Kipnes, Edmund Luo, Fanurik Hootan Khatami, Peter P. Stein, Aarhus, Denmark, San Antonio, TX, Rahway, NJ. Presented at the 67th A.D.A. Meeting & Scientific Sessions, June 22 through 26, 2007, Chicago, IL.

Safety and Pharmacodynamics of CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled, Double-Blind, Dose-Escalation Study. MAGGIE WANG, MARK KIPNES, STEPHANIE MATHESON, STELLA WEN, BETTY LAWRENCE, KAREN THIBAudeau, JEAN-PAUL CASTAIGEN, THOMAS ULRICH, Montreal, PQ, Canada, San Antonio, Texas. Presented at the 67th A.D.A. Meeting & Scientific Sessions, June 22 through 26, 2007, Chicago, IL.

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, in Patients with Type 2 Diabetes Mellitus Inadequately controlled on Glimepiride Alone or on Glimepiride and Metformin. Kjeld Hermansen, MD¹, Mark Kipnes, MD², Edmund Lui, Ph.D.³, Debra Fanurik, Ph.D., Hootan Khatami, MD¹, Peter Stein, MD¹, for the Sitagliptin Study 035 Group.¹ Aarhus University Hospital, Aarhus, Denmark;²Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA; ³Merck Research Laboratories, Rahway, NJ, USA; *See online appendix for list of Sitagliptin Study 035 investigators. Diabetes, Obesity and Metabolism. June 2007.

Sitagliptin Monotherapy Improved Glycemic Control in the Fasting and Postprandial States and Beta-Cell Function after 24 Weeks in Patients with Type 2 Diabetes (T2DM). PABLO ASCHNER, MARK KIPNES, JARED LUNCEFORD, CAROLYN MICKEL, MICHAEL


"Co-Administrator of MK-0431 and Metformin in Patients with Type 2 Diabetes Does Not Alter the Pharmacokinetics of MK-0431 or Metformin." GARY HERMAN, ARTHUR BERGMAN, BINGMING YI, CATHY STEVENS, ALAN XIAO, LI CHEN, AMY WANG, WEI ZENG, MICHAEL DAVIES, MARK KIPNES, JOHN WAGNER. Rahway, NJ; West Point, PA; San Antonio, TX. Presented at the 65th Scientific Sessions. Friday June 10 – Tuesday June 14, 2005. The San Diego Convention Center, San Diego, California

"Efficacy of Tadalafil for the Treatment of Erectile Dysfunction in Men with Diabetes; Results from MOMENTUS (Multiple Observations in Men with ED in National Tadalafil Study in the US). SAM ENGEL, LEONARD MARKS, MARK S. KIPNES, MICHAEL A. MARX, FANNI NATANEGARA, David G. WONG, SANJEEV AHUJA. Norwalk, CT; Culver City, CA; San Antonio, TX; Indianapolis, IN. Presented at the 65th Scientific Sessions. Friday June 10 – Tuesday June 14, 2005. The San Diego Convention Center, San Diego, California


"Effect of Mitemcinal Fumarate (GM-611) on Gastric Emptying, Safety and Tolerability with Diabetic or Idiopathic Gastroparesis." Endo 2004 Meeting for poster presentation. Friday, June 18, 2004, 11:00 to 12:00 & 2:30 p.m. to 3:30 p.m., Exhibit Hall, Poster Board # P3-577. Chugai Pharma.

Effect of Mitemcinal Fumarate (GM-611) on Gastric Emptying in Patients with Idiopathic or Diabetic Gastroparesis*: Digestive Disease Week (DDW) 2004 meeting for a AGA Poster Session in May. Tuesday, May 18, 2004, Abstract ID#: 103158, Poster Session ID#: 1817, Session Type: Gastric Motility and Sensation. 12:00 to 2:00 p.m.

“Comparing the Efficacy and Tolerability of Metformin XT QD to Immediate-Release Metformin BIDD In Patients with Type 2 Diabetes”: AACE 2004 as a poster presentation. Mark S. Kipnes, MD1, Prachi K. Dandekar, Pharm.D.2. Friday, April 30, 2004 from 9:45 to 10:30 a.m. Andrx Labs, Inc., 411 Hackensack Ave., Hackensack, New Jersey 07601, U.S.A.
“Comparison of Extended-Release Metformin with the Evening Meal to Immediate-Release Metformin bid in Type 2 Diabetes. Mark S. Kipnes, MD1, Prachi K. Dandekar, Pharm.D.2. Friday, April 30, 2004 from 9:45 to 10:30 a.m. Andrx Labs., Inc., 411 Hackensack Ave., Hackensack, New Jersey 07601, U.S.A.


“Twelve-Month Effectiveness of Insulin Glargine Use in Diabetic Patients from an Endocrinology Specialty Practice”. JEROME S. FISCHER, CRAIG S. ROBERTS, TRENT MCLAUGHLIN, LITZA LOZA, REBECCA BEAUCHAMP, LAURA ANTELL, SHERWYN SCHWARTZ, MARK KIPNES. San Antonio, TX; Yardley, PA; Bridgewater NJ. Scientific Sessions – A.D.A. Annual Meeting – American Diabetes Association.


“Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study. Daniel Einhorn MD1, Marc Rendell, MD2, James Rosenzweig, MD3, John W. Egan,4 Annette L. Mathisen, PhD4 and Roberta L. Schneider, MD4, for the Pioglitazone 027 Study Group*. 1Diabetes and Endocrine Associates and Sharp HealthCare, San Diego, California, 2Creighton Diabetes Center, Omaha, Nebraska, and the Rose Salter Medical Research Foundation, Baltimore, Maryland, 3Joslin Diabetes Center, Boston, Massachusetts, and 4Takeda America Research and Development Center, Inc, Princeton, New Jersey. Clinical Therapeutics.2000;22:1395-1409. Parts of this work were presented at the 59th Annual Meeting and Scientific Sessions of the American Diabetes Association, June 19-20, 1999, San Diego, California, and published as an abstract in Diabetes, Supplement 1, May 1999. *Members of the Pioglitazone 027 Study Group are listed in the Acknowledgements. *Mark S. Kipnes: Part of 027 the Study Group.


DOES GASTRIC EMPTING STATUS IN PATIENTS WITH DIABETES INFLUENCE THE EFFECTIVENESS OF DOMPERIDONE? D. Patterson, Seattle, WA; D. Silvers, Meltaire, LA; M. Kipnes, San Antonio, TX; V. Broadstone, Louisville, KY; EMM. Quigley, Omaha, NE; R.

*M. S. Kipnes – member of study group


Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naïve Type 2 Diabetic Patients After 24 Weeks of Treatment Itamart Raz; Vivian Fonseca; Mark S. Kipnes; Raffaella Balena – Diabetes Care, March 2012

Response to Topical Capsaicin Correlates With The Efficacy of Topical Clonidine As a Treatment For Painful Diabetic Neuropathy (PDN) J. N. Campbell; Mark Kipnes; Michael C. Rowbotham; W. K. Schmidt – September 2011 Conference Paper Meeting of Peripheral Nerve Society.


Topical Clonidine for Treatment of Painful Diabetic Neuropathy: A Randomized Double Blind Phase IIb Clinical Trial. AUTHORS: 1. James N. Campbell, Prof., MD, jcampbell@arciontherapeutics.com, 410-522-8701, Arcion Therapeutics, Baltimore, MD, United States. 2. Mark S. Kipnes, Dr., MD, mkipnes@dgdclinic.com, 210-614-8612, Cetero Research/ Diabetes and Glandular Disease Center, San Antonio, TX, United States. 3. Michael C. Rowbotham, Prof., MD, RowbothM@cpmcri.org, 415-600-1600, California Pacific Medical Center Research Institute, Scientific Director, San Francisco, CA, United States. 4. Karin L. Petersen, Prof., MD, karin.petersen@ucsf.edu, 415-885-7814, University of California, Neurology, San Francisco, CA, United States. 5. Bruce C. Stouch, Dr., PhD, bstouch@arciontherapeutics.com, 610-356-8658, Arcion Therapeutics, Baltimore, MD, United States. 6. Margaret Kelly, Ms., MS, mkelly@arciontherapeutics.com, 540-525-7335, Arcion Therapeutics, Baltimore, MD, United States. 7. Claudia M. Campbell, Dr., PhD,
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-875, a Novel GPR40 Agonist, Following Once-Daily Administration for 2 Weeks in Type 2 Diabetic Subjects. Authors: Eckhard Leifke1*, Jingtao Wu1, Prabhakar Viswanathan1, Mark Kipnes2, Majid Vakilynejad1 Takeda Global Research & Development Center, Inc., Deerfield, IL; 2dgd Research, San Antonio, TX

Presented at the ADA 71st Scientific Sessions, San Diego, CA, June 24-28, 2011

A Novel Human Growth Hormone XTEN Construct (VRS-317) for Once-a-Month Subcutaneous Administration in a Phase 1a Study of Growth Hormone-Deficient Adults. Jeffrey L. Cleland1, Nathan Geethring2, Benjamin Spink2, Soha Motlagh2, Yi Yao2, Joshua Silverman2, and Mark S. Kipnes3. Presented at the Endocrine Society's 93rd Annual Meeting & Expo, June 4-7, 2011 – Boston


Taspoglutide, a Once-Weekly Human GLP-1 Analog, as Monotherapy Significantly Lowera A1c and Body Weight in Patients with Type 2 Diabetes (T2D): Results from the T-Emerge 1 Phase 3 Trial. Itamar Raz, Vivian Fonseca, Mark Kipnes, Laurence Durrwell, John Hoeckstra, Mark Boldrin, Raffaella Balena. Presented at the American Diabetes Association 70th Scientific Sessions in Orlando, FL June 25th through 29th, 2010.


Alogliptin Added to Sulfonylurea Therapy in Patients with Type 2 Diabetes Reduces HbA1c without Increasing Hypoglycemia. Richard Platley, Mark Kipnes, Penny Fleck, Craig Wilson, Qais Mekki, Burlington, VT, San Antonio, TX, Deerfield, IL. Selected for Poster Presentation at the American Diabetes Association 68th Scientific Sessions, June 6-10, 2008 in San Francisco, CA. Also, printed in the Scientific Sessions Abstract Book, the June 2008 supplement to the journal, Diabetes.


A Phase II, Multi-center, Multi-dose Study of an Extended-release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults. Randall J. Urban1, Mark Kipnes2, Susie Estes3, Stephen J. Winters3, Sujit K. Basu4, Ken Loveday4, Lisa A. Herman4, Frederick T. Murray4 and Alan Kimura4. 1. University of Texas Medical Branch, Galveston TX, United States;
Safety and Pharmacodynamics of CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled, Double-Blind, Dose-Escalation Study. Maggie Wang, Mark Kipnes, Stephanie Matheson, Stella Wen, Betty Lawrence, Karen Thibaudeau, Jean-Paul Castaigen, Thomas Ulrich, Montreal, PQ, Canada, San Antonio, Texas. Poster Presentation at the 67th A.D.A. Meeting & Scientific Sessions, June 22 through 26, 2007, Chicago, IL.

Effects of Renal Impairment on The Pharmacokinetics of Sorafenib And Its Metabolites. Smith V1, Marbury T1, Kipnes M3, Cihon F4, Lettieri J4, Mazzu A4. 1Orleans Center for Clinical Research, Knoxville Affiliate, Knoxville, TN; 2Orlando Clinical Research Center, Orlando, FL; 3Diabetes and Glandular Disease Clinic, PA, San Antonio, TX; 4Bayer Pharmaceuticals Corporation, West Haven, CT, USA. Poster for Sorafenib Renal Study, 11804, to be presented at the AACR Meeting, April 2007.

Time Course of Body Composition Changes Following Pioglitazone in Patients with Type 2 Diabetes: Increase in Body Fluid is Detected Earlier (at 24-Weeks) Than Fat Mass (at 4-8 Weeks). NAOTO UEMURA, SMITA ABBI, ANDREW E. DENKER, HAMISH WRIGHT, GOUTAM MISTRY, ALLISON MOREAU, CHARLES BOWDEN, MARK S. KIPNES, ANDREW AHMANN, NORMAN n. LUNDE, GARY MEININGER, CHAU THACH, KIMBERLY BRODOVICZ, KEITH GOTTESDIENER, JOHN WAGNER. Rahway, NJ; San Diego, CA; San Antonio, TX; Portland OR; St. Paul, MN. Late Breaking Abstract at the 66th Scientific Sessions, A.D.A. Meeting June 9-13, 2006, Washington D.C.

"A Phase 1 Clinical Trial of a Zinc Finger DNA-Binding Protein (ZFP) Activator (STABLE-509) of Vascular Endothelial Growth Factor (VEGF) in Subjects with Diabetic Neuropathy (DN)." Poster presentation number PO5.101. Selected for presentation at the 58th American Academy of Neurology Annual Meeting, April 1-8, 2006, at the San Diego Convention Center in San Diego, California.


Treatment of Combined Hyperlipidemia with Simvastatin plus Fenofibrate. S.M. Grundy, MD1, G.L. Vega, PhD1, Z. Yuan, MD, PhD2, J. Palmisano, MD2 for the SAFARI Study Group.* Poster presented at the A.D.A. meeting, June, 2004.

Effect on LDL Pattern Distribution of Treatment with Simvastatin plus Fenofibrate in Patients with Combined Hyperlipidemia. S.M. Grundy, MD1, G.L. Vega, PhD1, Z. Yuan, MD, Ph.D.2, W. Battisti, PhD2, J. Palmisano, MD2 for the SAFARI Study Group.* Poster presented at the Endocrine Society Meeting, June 2004.

Safety of Metemcinal Fumarate (GM-611) in Patients with Symptomatic Gastroparesis*: Poster presented at the 2004 A.D.A. Meeting, Saturday June 5, 2004, 12:15 to 2:15 p.m. & 5:00 p.m. to 6:00 p.m.

Effect of Metemcinal Fumarate (GM-61) on Gastric Emptying in Patients with Idiopathic or Diabetic Gastroparesis*: Digestive Disease Week (DDW) 2004 meeting for a AGA Poster Session in May. Tuesday, May 18, 2004, Abstract ID#: 103158, Poster Session ID#: 1817, Session Type: Gastric Motility and Sensation. 12:00 to 2:00 p.m.

Impact of Achieved Systolic Blood Pressure on Renal Function in Type 2 Diabetic Nephropathy. Marc A. Pohl, MD1; Samuel Blumenthal, MD2; Lawrence G. Hunsicker, MD3 and The Collaborative Study Group4. 1Cleveland Clinic Fdn., Cleveland Ohio; 2Veterans Administration, Milwaukee, Wisconsin; 3University of Iowa Hospitals and Clinics, Iowa City, Iowa and 4Rush Medical College, Chicago, Illinois. Presented at the ASN Meeting, November 2002.

Impact of Angiotensin Receptor Blockade with Irbesartan On Renal Function at Different Systolic Blood Pressure (SBP) Levels in Type 2 Diabetic Nephropathy. Marc A. Pohl, MD1; Daniel J. Cordonnier, MD2; Samuel Spitalewitz, MD3 and The Collaborative Study Group4.

The Presence of Retinopathy Is Associated with Poor Renal and Cardiovascular Outcomes In Type 2 Diabetic Nephropathy. Roger Rodby, MD1; Richard Gilbert, MD2, for **The Collaborative Study Group**, 1Chicago, Illinois USA. 2Victoria, Australia. Presented at the ASN Meeting, November 2002.

Predictors of The Progression of Renal Insufficiency in Patients with Type 2 Diabetes And Overt Diabetic Nephropathy. John P. Middleton, Julia Lewis, for **The Collaborative Study Group** University of Texas Southwestern, Dallas, Texas; Vanderbilt University, Nashville, Tennessee. Presented at the ASN Meeting, November 2002.

Cardiovascular Outcomes in The Irbesartan Diabetic Nephropathy Trial (IDNT) Of Patients with Type 2 Diabetes and Overt Nephropathy. Tomas Berl, MD1 for **The Collaborative Study Group** 1Division of Renal Diseases and Hypertension, University of Colorado2, Denver, Colorado Department of Medicine, Rush Medical Center, Chicago, Illinois. Presented at the ASN Meeting, November 2002.

“Albutropin™ In Subjects with Adult Growth Hormone Deficiency.” Anne Klibanski, M.D.1, Mark Kipnes, M.D.2, David Kleinberg, M.D. 3, David Cook, M.D.4, Peter Snyder, M.D.5, Maria Walker6 and Daniel Odenheimer, PhD7. 1Massachusetts General Hospital, Boston, MA, 02114; 2Diabetes and Glandular Disease Clinic, San Antonio, TX 78229; 3New York University School of Medicine, New York, NY, 11016; 4Oregon Health Sciences University, Portland, OR, 97201; 5University of Pennsylvania, Philadelphia PA, 19104; 6Human Genome Sciences, Rockville, MD, 20850; 7Human Genome Sciences, Rockville, MD, 20850. Presented at the First Joint Symposium GH-IGF-2002. October 8, 2002.


“Glycemia control and Lipid Profile in Type 2 Diabetes are Improved by Long-Term Pioglitazone/Sulfonylurea Combination Therapy.” M. Menon-Raju, M. Kipnes, and NB Glazer. Takeda Pharmaceuticals North American, Inc., Lincolnshire, IL, USA; Diabetes & Glandular Disease Clinic, San Antonio, TX, USA. Presented at The Diabetes UK Annual Conference, March 13-15, 2002. Birmingham, UK.

“Glycemic Control in Type 2 Diabetes is Improved by Long-Term Pioglitazone/Sulfonylurea Combination Therapy.” M. Kipnes1 and A. Boss.2 For presentation at the 37th Annual Meeting of the European Association for the Study of Diabetes. September 9 – 13, 2001. Glasgow, Scotland. Hosted by Diabetes UK. Dr. Michael Hall Chairman.

“The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus”. Mark S. Kipnes, Paresh Dandona, J. Gordon Still, Gordana Kosutic. Diabetes and Glandular Disease Clinic, San Antonio, TX; Diabetes-Endocrinology
Center of Western, Buffalo, NY; Nobex Corporation, Research Triangle, NC. For presentation at the President's Poster Session and Reception, American Diabetes Association 61st Scientific Sessions, Sunday, June 24, 2001, Philadelphia Pennsylvania.


A Clinical Trial In Patients With Overt Type 2 Diabetic Nephropathy. EJ Lewis; LG Hunsicker; WC Clarke for The Collaborative Study Group, Chicago IL and Iowa City, Iowa. Presented at the ASN meeting November 2001.


“Pharmacokinetics and Pharmacodynamics of Pulmonary Insulin Delivered via the AERx® Insulin Diabetes Management System in Type 1 Diabetics”. M. Kipnes, B. O'tulana, S. Farr, J. Jendle, J. Thippahwong and S. Schwartz. For presentation at the 36th Annual Meeting of The European Association for the Study of Diabetes, held at the Jerusalem ICC - International Convention Center and the adjacent Crowne Plaza Hotel, September 18, 2000, Jerusalem, Israel.

“Effects of Troglitazone on HbAlc and ALT Levels in Clinical Practice”. Sherwyn L. Schwartz, M.D., Jerome S. Fischer, M.D., Mark S. Kipnes, M.D., San Antonio, TX. For presentation at the President’s Poster Session and Reception, American Diabetes Association 59th Scientific Sessions, June 20, 1999, San Diego, CA.

* M.S. Kipnes – member of study group

ORAL PRESENTATIONS

CLINICAL – What’s New in Diagnosis & Treatment of GH Dysfunction? Oral Sessions. AEZS-130 (Maclmorelin)-Stimulated GH Test: Validation of a Novel Test For The Diagnosis of Adult Growth Hormone Deficiency (AGHD). Jose M. Garcia; Ronald S. Swerdloff; Christina Wang; Michael Kyle; Mark Kipnes; Beverly MK Biller; David Cook; Kevin CJ Yuen; Vivien Bonert; Adrian Dobs; Mark Molitch; George Merriam. Medicine, Molecular and Cell Biology, MEDVAMC, Baylor College of Medicine, Houston, TX, Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA; Radiant Research, Inc, Chicago, IL; DGD Clinic, San Antonio, TX; Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA; Medicine, Oregon Health & Science University, Portland, OR; Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; Medicine Johns Hopkins Medical Institutions, Baltimore, MD; Medicine, Northwestern University, Chicago, IL; Medicine, VA Puget Sound Health Care System/University of Washington, Seattle and Tacoma, WA. Presented at The Endocrine Society’s 94th Annual Meeting & Expo – Houston, TX June 23-26, 2012.

CLINICAL – What’s New in Diagnosis & Treatment of GH Dysfunction? Oral Sessions. A Phase 1 Trial of Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of a New Human Growth Hormone Analogue (VRS-317) for Monthly Subcutaneous Administration in Adults with Growth Hormone Deficiency. Timothy Bailey, BMK Biller; Gerard S. Conway; Mark Kipnes; Vera Popova-Brick; Kevin CJ Yuen; Eric Humphriss; George M. Bright; Jeffrey L. Cleland. Endocrinology, AMCR Institute, Escondido, CA; Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA; Endocrinology, University College London Hospitals, London, UK; Endocrinology, DGD Clinic, San Antonio, TX; Endocrinology, University Clinic Center, Belgrade, Serbia; Endocrinology, Diabetes and Clinical Nutrition; Oregon Health Sciences University, Portland, OR; Clinical Operations, Versartis Inc., Redwood City, CA; Medical Affairs,
